HIV-Associated Nephropathy Market Size, Share, and Growth Forecast, 2026 - 2033

The global HIV-associated nephropathy market size is likely to be valued at US$ 29.7 billion in 2026 and is expected to reach US$ 39.3 billion by 2033, growing at a CAGR of 4.1% between 2026 and 2033, driven by continued demand for antiretroviral therapy (ART), improved recognition of HIV-related kidney complications, and increasing attention to chronic kidney disease among people living with HIV.

Antiretroviral therapy remains the cornerstone of HIV-associated nephropathy (HIVAN) management, helping control the underlying infection and reduce the risk of kidney disease progression. Demand for kidney-function monitoring, supportive renal medicines, dialysis, and transplantation services also contributes to market development. Growth will depend on treatment accessibility, diagnostic capacity, and the availability of specialized kidney care.

Drivers - Expanding access to antiretroviral therapy and sustained HIV management

The expansion of HIV treatment programs is a major driver of demand for medicines and healthcare services relevant to HIVAN. According to UNAIDS, approximately 41.0 million people were living with HIV worldwide in 2025, while 32.1 million were receiving antiretroviral therapy. These figures highlight the substantial population requiring continuing treatment, monitoring, and management of associated health complications. Clinical guidelines recommend initiating ART promptly after HIV diagnosis and using ART to manage suspected or confirmed HIVAN. Effective viral suppression can help reduce the risk of kidney disease progression.

The commercial impact extends beyond antiretroviral prescriptions. Long-term HIV management creates demand for renal-function testing, urine-protein assessment, medication reviews, and coordinated HIV and nephrology services. Pharmaceutical companies can benefit from sustained demand for appropriate treatment regimens, while diagnostic providers and healthcare networks can expand their role in monitoring kidney health. The extent of this opportunity depends on treatment adherence, affordability, and the integration of kidney screening into routine HIV care.

Improved Recognition of HIV-Related Kidney Disease and Genetic Susceptibility

Greater understanding of HIVAN, chronic kidney disease, and genetic susceptibility is strengthening the need for targeted kidney monitoring. Variants in the APOL1 gene are associated with an increased risk of certain kidney disorders, including focal segmental glomerulosclerosis, a lesion that can occur in HIVAN. Research involving populations in West Africa has contributed to a better understanding of APOL1-associated kidney disease and its clinical significance. However, genetic susceptibility does not establish that an individual will develop HIVAN, and genetic findings should be interpreted alongside clinical evidence.

Improved recognition of kidney complications creates opportunities for diagnostic testing, specialist referral, and more appropriate treatment selection. Earlier identification of renal abnormalities can help clinicians investigate potential causes before substantial kidney damage develops. For the market, this supports demand for laboratory services, clinical monitoring systems, and integrated care pathways. Providers that connect HIV treatment services with nephrology expertise may be better positioned to identify complications and support timely intervention, particularly in healthcare systems where specialist services remain difficult to access.

Restraint - Diagnostic Complexity, Treatment Affordability, and Uneven Access to Specialist Care

HIVAN can be difficult to distinguish from other kidney disorders affecting people living with HIV. These include HIV-associated immune-complex kidney disease, medication-related kidney injury, and unrelated forms of chronic kidney disease. Accurate diagnosis may require kidney-function assessment, urine testing, imaging, and, where clinically indicated, a renal biopsy. These procedures depend on trained healthcare professionals, laboratory capacity, and access to specialist services.

Treatment costs become more significant when patients develop advanced chronic kidney disease or require dialysis or transplantation. In lower-resource settings, limited diagnostic infrastructure, medication affordability, specialist shortages, and dependence on public healthcare funding can interrupt continuity of care. These barriers may delay diagnosis and reduce access to appropriate treatment. For market participants, the central challenge is to expand treatment and monitoring while maintaining affordability and reliable supply. Companies must also account for differences in healthcare funding, reimbursement, and treatment access across regions.

Opportunities - Integrating HIV and Nephrology Services in High-Burden Markets

Integrating kidney screening into established HIV treatment programs presents an important opportunity to improve HIVAN management. Routine assessment of estimated glomerular filtration rate, urine abnormalities, and medication-related kidney risks can help clinicians identify patients who need further investigation. Clinical guidance recommends regular kidney-function monitoring among people living with HIV, with the frequency of assessment influenced by individual risk factors and clinical circumstances.

This approach is particularly relevant in countries with substantial HIV burdens, including South Africa and Nigeria. Healthcare systems can strengthen standardized laboratory protocols, clinician training, referral coordination, and access to affordable diagnostic services. Diagnostic manufacturers may benefit from increased demand for renal-function tests, while pharmaceutical suppliers can support treatment continuity through dependable procurement and distribution. Healthcare providers can also develop integrated HIV and kidney-care pathways. Successful implementation will depend on funding, laboratory capacity, workforce availability, and the ability to connect abnormal screening results with appropriate clinical care.

Kidney-Conscious Treatment Selection and Advances in HIV Therapeutics

Advances in antiretroviral therapy create opportunities to improve treatment selection for people living with HIV who also have impaired kidney function. Certain antiretroviral medicines require dose adjustments or additional precautions in patients with renal impairment. For example, clinical guidance identifies kidney-related considerations when selecting tenofovir-based regimens, particularly those containing tenofovir disoproxil fumarate. Treatment decisions must account for renal function, drug interactions, hepatitis B status, resistance patterns, and the patient's overall clinical condition.

Long-acting formulations and newer combination regimens may improve treatment convenience for eligible patients, although they do not independently establish a treatment for HIVAN. Commercial opportunities include the development of suitable formulations, renal-safety research, clinical decision-support tools, and partnerships between pharmaceutical companies and specialist healthcare providers. Companies that demonstrate appropriate clinical evidence and maintain access across different healthcare systems can strengthen their position in the broader HIV-treatment market. The principal limitation is that most antiretroviral innovations target HIV infection rather than kidney damage specifically associated with HIVAN.

Treatment Type Insights

Antiretroviral therapy is likely to be the leading treatment category, with an anticipated market share of 59.5%. ART targets the underlying HIV infection and remains central to HIVAN management by helping suppress viral replication and reduce the risk of kidney disease progression. Examples include integrase strand transfer inhibitor-based regimens and other combination therapies selected according to viral suppression, drug resistance, tolerability, and kidney function. Demand is supported by long-term HIV treatment requirements and the need for kidney-conscious medication selection.

Renal-replacement therapy is anticipated to be the fastest-growing category. It includes hemodialysis and peritoneal dialysis for patients with advanced kidney failure. Growth opportunities are associated with expanding dialysis access and increasing demand for specialized renal care.

However, renal-replacement therapy represents treatment for severe kidney dysfunction rather than a substitute for early HIV management. Other categories include renin-angiotensin-aldosterone system inhibitors, such as ACE inhibitors and angiotensin receptor blockers, which may help manage proteinuria in appropriate patients; corticosteroids, which may be considered in selected biopsy-confirmed HIVAN cases; and kidney transplantation for eligible patients with kidney failure. Each intervention serves a distinct clinical purpose.

Disease Stage Insights

Proteinuric HIVAN with preserved or moderately reduced kidney function is the leading disease-stage category, with an anticipated market share of 43.6% in 2026. Patients in this segment may receive ART, regular kidney-function monitoring, blood-pressure management, and treatment for proteinuria. For example, clinicians may monitor estimated glomerular filtration rate and urine albumin or protein levels to assess kidney health and determine whether further investigation is needed. Early identification can support timely intervention and help limit disease progression. However, proteinuria alone does not confirm HIVAN, as other kidney disorders can produce similar symptoms.

End-stage kidney disease is anticipated to be the fastest-growing category. Patients may require hemodialysis, peritoneal dialysis, or kidney transplantation, depending on their clinical condition and eligibility. This segment creates demand for dialysis equipment, consumables, specialist renal services, and transplant-related care. Other categories include advanced chronic kidney disease, acute kidney injury or rapidly progressive HIVAN, and HIV-associated immune-complex kidney disease and mixed nephropathies.

For example, patients with rapidly declining kidney function may require urgent nephrology assessment, while suspected immune-complex disease may warrant additional diagnostic evaluation. These differences shape treatment intensity, resource utilization, and demand for specialized care.

North America HIV-Associated Nephropathy Market Trends

North America benefits from established HIV-treatment infrastructure, specialist nephrology services, advanced diagnostics, and pharmaceutical innovation. The U.S. is the region’s principal market, supported by continued demand for antiretroviral therapy (ART), kidney-function monitoring, and treatment for advanced kidney disease. The Centers for Disease Control and Prevention reported 1,158,701 people aged 13 years and older living with diagnosed HIV in the U.S. and its territories at the end of 2024. This population supports ongoing demand for HIV care, although it does not indicate HIV-associated nephropathy (HIVAN) prevalence.

U.S. HIV-Associated Nephropathy Market Trends

The U.S. market benefits from broad access to established HIV medicines, including Gilead Sciences’ Biktarvy, a combination antiretroviral treatment. Such therapies support viral suppression, an important component of HIVAN management, while renal monitoring helps clinicians assess kidney function and guide medication selection. In June 2025, the U.S. Food and Drug Administration approved Gilead’s Yeztugo (lenacapavir) for HIV-1 pre-exposure prophylaxis. Although it is a prevention product rather than an HIVAN treatment, the approval illustrates continued investment in HIV innovation and the wider clinical infrastructure surrounding HIV care. Opportunities include integrated infectious-disease and nephrology services, laboratory testing, and treatment optimization. However, insurance coverage, affordability, and unequal access to specialist care continue to influence outcomes.

Middle East & Africa HIV-Associated Nephropathy Market Trends

The Middle East & Africa is identified as the leading region, with an estimated 60.3% market share, reflecting the substantial HIV burden in sub-Saharan Africa. This commercial estimate should not be interpreted as the region’s share of global HIVAN cases. Regional demand depends on ART access, kidney-disease recognition, diagnostic capacity, public procurement, and the availability of dialysis and specialist services.

South Africa HIV-Associated Nephropathy Market Trends

South Africa is a major market owing to its extensive public HIV-treatment program and continuing efforts to expand treatment access. Generic antiretroviral suppliers, including Aspen Pharmacare, contribute to the wider regional pharmaceutical supply landscape. Greater ART coverage can support HIVAN management by improving control of HIV infection, while integrating kidney-function testing into routine HIV services could strengthen early detection. Nevertheless, limited nephrology capacity and unequal access to renal-replacement therapy remain barriers for patients with advanced disease.

Nigeria HIV-Associated Nephropathy Market Trends

Nigeria’s large population and substantial HIV burden make it another important market. Public-sector treatment programs and international health partnerships influence medicine availability and continuity of care. Expanding ART delivery through established HIV clinics creates opportunities to incorporate renal screening and referrals. However, diagnostic access, affordability, and limited specialist infrastructure can delay recognition and management of HIVAN. Investment in laboratory networks, clinician training, and accessible renal services could help address these gaps.

Asia Pacific HIV-Associated Nephropathy Market Trends

Asia Pacific is anticipated to be the fastest-growing regional market, supported by expanding HIV-care programs, generic pharmaceutical production, and improvements in diagnostic and specialist services. Growth will depend on converting broader HIV-treatment access into earlier recognition of kidney complications and better access to renal care.

India HIV-Associated Nephropathy Market Trends

India is an important supplier of affordable generic antiretroviral medicines. Companies such as Cipla support access to HIV medicines through their antiretroviral portfolios, while domestic manufacturing capabilities can help strengthen supply in price-sensitive markets. Wider availability of ART can support HIVAN management, but additional investment in renal-function testing, nephrology referrals, and dialysis access is necessary to address kidney complications. Opportunities include partnerships with hospitals, diagnostic laboratories, and public-health programs to integrate kidney monitoring into long-term HIV care.

China HIV-Associated Nephropathy Market Trends

China combines substantial healthcare infrastructure with national HIV programs and pharmaceutical-sector capabilities. In July 2024, UNAIDS and Chinese public-health authorities signed strategic agreements to strengthen collaboration on the HIV response, including efforts connected with global development and ending AIDS. This cooperation may support broader treatment access and health-system coordination. For the HIVAN market, the opportunity lies in improving awareness of HIV-related kidney disease, strengthening diagnostic pathways, and connecting HIV services with nephrology care. Country-specific medicine registration, reimbursement, and procurement requirements will remain important considerations for companies entering the market.

Across Asia Pacific, investment opportunities include generic antiretroviral supply, laboratory testing, dialysis capacity, and clinician training. Companies should assess national treatment coverage and specialist-care availability individually, as pharmaceutical access alone cannot ensure timely diagnosis or effective HIVAN management.

The global HIVAN-related treatment ecosystem includes branded and generic antiretroviral medicines, supportive renal medicines, diagnostics, dialysis equipment, and specialist healthcare services. Gilead Sciences, ViiV Healthcare, and Merck & Co. are important participants in the broader HIV-treatment industry. Generic pharmaceutical manufacturers, including Cipla, Aurobindo Pharma, and Hetero, support antiretroviral access, while kidney-care companies supply equipment, consumables, and treatment services.

Market participants focus on treatment innovation, generic manufacturing, distribution expansion, and partnerships that improve patient access. Branded pharmaceutical companies prioritize clinical differentiation, formulation development, and regulatory approvals, while generic manufacturers compete on cost, manufacturing scale, and supply reliability. Kidney-care companies focus on dialysis equipment, consumables, and service delivery. Key differentiators include clinical evidence, affordability, dependable supply, appropriate treatment selection, and access to specialized care.

Key Industry Developments:

• In April 2026, Merck received U.S. FDA approval for IDVYNSO (doravirine/islatravir), a once-daily, two-drug HIV treatment for adults whose virus is suppressed on a stable regimen and who meet the product’s eligibility criteria.
• In August 2026, Gilead Sciences received U.S. FDA approval for Bixlenvo, a once-daily single-tablet HIV treatment combining bictegravir and lenacapavir for eligible adults with virologically suppressed HIV.